Skip to main content
ABSI
NASDAQ Industrial Applications And Services

Absci Q3 Revenue Misses by Half; Hair-Loss Data Readout Set for December

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.85
Mkt Cap
$1.737B
52W Low
$2.24
52W High
$12.545
52W Position info
340% above low
Off High info
21% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

ABSI has more than doubled off its 52-week low of $2.24.

Summary

Absci's Q3 revenue of $0.3 million missed the $727.1 thousand estimate and the net loss widened to $33.3 million, but $173.7 million in cash funds operations into the second half of 2028. The next hard event is 13-week interim ABS-201 proof-of-concept data in pattern hair loss, expected December 2026.


Key Events · Earnings and Guidance · ABSI

  • Q3 Revenue Misses Consensus by Half

    Revenue was $0.3 million versus $0.4 million a year ago and an IBES estimate of $727.1 thousand; net loss widened to $33.3 million from $28.7 million.

  • Cash Funds Operations Into 2H 2028

    Cash, cash equivalents and marketable securities were $173.7 million at September 30, 2026, down from $201.1 million at June 30, 2026, with runway guided into the second half of 2028.

  • ABS-201 Hair-Loss Data Due December

    13-week interim proof-of-concept data from the HEADLINE trial in pattern hair loss is anticipated in December 2026, with full 26-week data in early 2027.

  • Endometriosis Phase 2 Details Outlined

    The planned STORYLINE Phase 2 trial would enroll approximately 150 patients across 10 or more countries, with initiation anticipated mid-2027.


Analysis · ABSI · Industrial Applications And Services

Revenue of $0.3 million came in well below the $727.1 thousand consensus, and the net loss widened to $33.3 million from $28.7 million a year ago as R&D spending climbed to $23.6 million. What offsets the miss is a $173.7 million cash pile that funds operations into the second half of 2028, so near-term financing pressure is not the issue. The real swing factor is the 13-week interim proof-of-concept data for ABS-201 in pattern hair loss, now guided to December 2026, with full 26-week data in early 2027 — that readout, not this quarter's revenue, will decide the stock.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABSI was trading at $9.85 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $2.24 to $12.54. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABSI - Latest Insights

ABSI
Nov 12, 2026, 7:06 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.74
Real-time Price: $9.85 info
Change: +$0.110 (+1%) info
Market Cap: $1.737B info
ABSI
Aug 11, 2026, 4:14 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $8.35
Real-time Price: $9.85 info
Change: +$1.50 (+18%) info
Market Cap: $1.737B info
ABSI
Aug 11, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.02
Real-time Price: $9.85 info
Change: +$1.83 (+23%) info
Market Cap: $1.737B info
ABSI
Aug 11, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.40
Real-time Price: $9.85 info
Change: +$1.45 (+17%) info
Market Cap: $1.737B info
ABSI
Jun 24, 2026, 4:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.08
Real-time Price: $9.85 info
Change: -$0.230 (-2%) info
Market Cap: $1.737B info